The invention relates to novel high-selectivity FABP4 inhibitors prepared from sulfonamide compounds or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The novel high-selectivity FABP4 inhibitors can be used for treating or preventing related metabolic diseases, mainly including insulin resistance, type 2 diabetes, atherosclerosis, hyperlipidemia, non-alcoholic fattyliver, etc. The sulfonamide compounds or the pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof are as shown in a formula which is described in the specification. In the formula, R0 is optionally selected from a group consisting of C1-C5 straight-chain or branched-chain alkyl groups, C3-C6 cycloalkyl groups and C1-C5 straight-chain and branched-chain alkoxy groups; R1 isoptionally selected from a group consisting of H, C1-C5 straight-chain or branched-chain alkyl groups, C3- C6 cycloalkyl groups and substituted benzyl groups; n is 0, 1 or 2; and A is a substituted and saturated/unsaturated aromatic ring.